Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 20, 2026, 6:02 PM
What would change this read
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)Origin Bio — Perturbation Biology in Real Tumors Patient-derived tumor perturbation platform and Axis regulatory DNA model.
Stage: Seed (YC) — specific raise amount not disclosed in indexed public sources.
Funding
MediumStage: Seed (YC) — specific raise amount not disclosed in indexed public sources.
Product / news
1 product/news‑styled row(s); headline risk without filings (High).
Verified facts
YC W26: AI and data for cancer therapeutics and regulatory sequence design.
Weak funding evidence: mention does not include a parsed raise amount/round and may refer to non-funding context.
No open roles indexed yet.
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source types found
Strongest / recent news-style rows
Wed, May 20, 06:02 PM · confidence 85%high quality
Wed, May 20, 06:02 PM · confidence 85%medium quality
Newest first · 3 event(s)
Source: Homepage
We generate multimodal cancer biology datasets from real patient tumor tissue, spanning spatial transcriptomics, morphology, proteomics, and ex vivo perturbation response.
YC W26: AI and data for cancer therapeutics and regulatory sequence design.
YC launch on Axis model outperforming AlphaGenome benchmarks.
1 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
We generate multimodal cancer biology datasets from real patient tumor tissue, spanning spatial transcriptomics, morphology, proteomics, and ex vivo perturbation response.
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗1 row(s)
Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.
YC launch on Axis model outperforming AlphaGenome benchmarks.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
YC W26: AI and data for cancer therapeutics and regulatory sequence design.
Why it matters: Funding signal — capitalization evidence; check the linked source for round, amount, and investors.
Open source ↗Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.